[Warner Pharmaceuticals: Subsidiary Receives Approval for Marketing Application of Beraprost Sodium] Warner Pharmaceuticals announced that its wholly-owned subsidiary, Hunan Warner Pharmaceutical Chiral Drug Co., Ltd., received the "Approval Notice for Marketing Application of Beraprost Sodium as a Chemical Raw Material" (Notice No.: 2026YS00386) issued by the National Medical Products Administration (NMPA), and has been publicized on the "Registration Information of Raw Materials, Excipients and Packaging" platform of the Center for Drug Evaluation (CDE) of the NMPA. Beraprost sodium is the raw material for beraprost sodium tablets. Beraprost sodium tablets are mainly used to improve symptoms such as ulcers, intermittent claudication, pain and coldness caused by chronic arterial occlusive disease.